DiagnaMed Adds New Launch Site of CERVAI™ Brain Health AI
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB:DGNMF), an artificial intelligence digital healthcare company, today announced it has added Drexel University as a new test launch site of CERVAI™, a world-first consumer brain health and wellness AI solution. The Company continues to expand its commercial initiatives in the U.S. and Canada for its CERVAI™ Brain Health AI Platform, which includes the BRAIN AGE® estimation solution, with world-class clinicians and hospital facilities such as the University of Miami Comprehensive Center for Brain Health, and in Canada’s leading research hospitals, such as Hamilton Health Sciences and St. Joe’s Healthcare Hamilton.
Related news for (DGNMF)
- DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
- DiagnaMed Cancels Previously Announced Private Placement
- DiagnaMed Announces LIFE Offering of up to $650,000
- DiagnaMed Announces Canadian Launch of BRAIN AGE® Brain Health AI